Quantcast
Last updated on April 16, 2014 at 8:44 EDT

OncoGenex to Webcast Discussion of Third Quarter 2012 Financial Results on Thursday, November 8, 2012

October 30, 2012

BOTHELL, WA and VANCOUVER, BC, Oct. 30, 2012 /PRNewswire/ – OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company’s
third quarter 2012 financial results will be released on Thursday,
November 8, 2012, and that the Company will host a conference call and
live webcast at 4:30 p.m. ET that afternoon. Management will discuss
the company’s financial results and provide an update on clinical
development programs for custirsen and OGX-427.

To access the webcast, log on to the Investor Relations page of the
OncoGenex website at www.oncogenex.com. Alternatively, you may access the live conference call by dialing
(877) 606-1416 (U.S. & Canada) or (707) 287-9313 (International). A
webcast replay will be available approximately two hours after the call
and will be archived on www.oncogenex.com for 90 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:
TEVA) have entered a global collaboration and license agreement to
develop and commercialize OncoGenex’ lead drug candidate, custirsen.
Custirsen is currently in Phase 3 clinical development as a treatment
in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer.
OGX-427 is in Phase 2 clinical development and OGX-225 is currently in
pre-clinical development. More information is available at www.OncoGenex.com.

ONCOGENEX’ FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning our anticipated product development activities,
such as expected clinical trial initiation and completion and
statements regarding the potential benefits and potential development
of our product candidates. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management’s current
expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ
materially from those described in the forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties,
including, among others, the risk that final trial results will not
demonstrate the same or any potential benefit as observed in
preliminary trial results, the risk that subsequent studies may not
confirm earlier trial results, the risk of delays in our expected
clinical trials, the risk that new developments in the rapidly evolving
cancer therapy landscape require changes in our clinical trial plans or
limit the potential benefits of our product, the risk that our cash
resources are insufficient to fund our planned activities for the time
period expected and the other factors described in our risk factors set
forth in our filings with the Securities and Exchange Commission from
time to time, including the Company’s Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q. The Company undertakes no obligation to
update the forward-looking statements contained herein or to reflect
events or circumstances occurring after the date hereof, other than as
may be required by applicable law.

SOURCE OncoGenex Pharmaceuticals, Inc.


Source: PR Newswire